<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04653779</url>
  </required_header>
  <id_info>
    <org_study_id>DA1229_01_DM_IV</org_study_id>
    <nct_id>NCT04653779</nct_id>
  </id_info>
  <brief_title>A Clinical Trial to Evaluate the Preference Regarding Convenience of Medication and Efficacy/Safety of SUGAMET®XR Tablet 5/1000mg</brief_title>
  <official_title>A Multi-center, Open-label, Single-arm, Phase IV Clinical Trial to Evaluate the Preference Regarding Convenience of Medication, Efficacy and Safety After Switching to SUGAMET®XR Tablet 5/1000mg in Patients With Type 2 Diabetes and Renal Diseases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dong-A ST Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dong-A ST Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multi-center, open-label, single arm study to Evaluate the preference regarding convenience&#xD;
      of medication, efficacy and safety of Sugamet XR tab. 5/1000mg in patients with Type 2&#xD;
      diabetes and renal diseases&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2020</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">May 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The preference regarding convenience of medication</measure>
    <time_frame>12 weeks</time_frame>
    <description>Looking back on the experience of participating in the study, which would you prefer, any of the existing DPP-4 inhibitor/metformin 1000mg sustained-release combination drug or the SugarMet® sustained-release tablet 5/1000mg?</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in HbA1c (%) After 12 weeks</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in HbA1C response rate(%) After 12 weeks</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Glycated albumin After 12 weeks</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in e-GFR After 12 weeks</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in UACR After 12 weeks</measure>
    <time_frame>12 weeks</time_frame>
    <description>Urine Albumin-to-Creatinin Ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in HbA1c (%) After 12 weeks NAG</measure>
    <time_frame>12 weeks</time_frame>
    <description>N-Acetyl-Glucosaminidase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Nephrin After 12 weeks</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Cystatin-C After 12 weeks</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TSQM-9 scores</measure>
    <time_frame>12 weeks</time_frame>
    <description>Treatment Satisfaction Questionnaire for Medication-9 scores, higher scores mean a better outcome.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">54</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <condition>Renal Disease</condition>
  <condition>Diabetes Mellitus</condition>
  <condition>Metabolic Disease</condition>
  <condition>Endocrine System Diseases</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive Evogliptin 5mg/Metformin 1000mg once a day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Evogliptin 5mg/Metformin 1000mg</intervention_name>
    <description>Size reduction of a tablet formulation</description>
    <arm_group_label>Group A</arm_group_label>
    <other_name>SUGAMET®XR tablet 5/1000mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Aged ≥60 years&#xD;
&#xD;
          -  Subjects with type 2 diabetes mellitus&#xD;
&#xD;
          -  Subjects treated with DPP-4 inhibitor and 1,000mg/day dose of metformin 1T/qd for at&#xD;
             least 8 weeks prior to screening&#xD;
&#xD;
          -  Subjects with HbA1c≤7.5% at screening&#xD;
&#xD;
          -  Subjects with 45mL/min/1.73m2≤eGFR≤90mL/min/1.73m2 at screening&#xD;
&#xD;
          -  Subjects with fasting glucose≤200 at screening&#xD;
&#xD;
          -  Subjects with 18.5kg/m2≤BMI≤40kg/m2 at screening&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with type 1 diabetes mellitus, secondary diabetes mellitus or gestational&#xD;
             diabetes mellitus&#xD;
&#xD;
          -  ESRD or Patients who have kidney dialysis&#xD;
&#xD;
          -  Subjects with ALT and AST 3 times or higher than upper normal range&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sung</last_name>
    <phone>82-2-920-8369</phone>
    <email>jhsung@donga.co.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Suncheonhyang Bucheon Hospital</name>
      <address>
        <city>Bucheon</city>
        <state>Gyeonggi</state>
        <zip>14584</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <contact>
      <last_name>Suncheonhyang Bucheon Hospital</last_name>
      <phone>82-32-621-6363</phone>
      <email>irb@schmc.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Bo Yeon Kim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Se-jong hospital</name>
      <address>
        <city>Bucheon</city>
        <state>Gyeonggi</state>
        <zip>14754</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <contact>
      <last_name>Se-jong hospital</last_name>
      <phone>82-32-340-1236</phone>
    </contact>
    <investigator>
      <last_name>Chong Hwa Kim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>November 19, 2020</study_first_submitted>
  <study_first_submitted_qc>November 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 4, 2020</study_first_posted>
  <last_update_submitted>December 10, 2020</last_update_submitted>
  <last_update_submitted_qc>December 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Metabolic Diseases</mesh_term>
    <mesh_term>Endocrine System Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

